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Abstract: In this review we want to summarize the results of the placebo-controlled randomized clinical trials with beta-
blocking adrenergic agents during electroconvulsive therapy (ECT), and review the effect on seizure duration and cardio-
vascular variables. We searched for studies in the electronic databases Medline. Keywords combined in the search were: 
“beta-adrenergic blocking agents” and “electroconvulsive therapy”. The only limitation specified in the search was that 
the publications should include only randomized controlled trials.  
Esmolol and other beta-blocking adrenergic agents can have a significant effect on seizure duration during ECT, it 
shortens seizure duration, and this effect is probably dose dependent. Therefore routine administration is not recom-
mended. 
Since the relation between seizure duration and efficacy of ECT is dependent on electrode placement it seems advisable to 
use bilateral electrode placement with patients with cardiovascular risk factors and an indication for use of esmolol dur-
ing every session before seizure induction.  
In the absence of cardiovascular risk factors but with prolonging hypertension or tachycardia during ECT sessions, es-
molol also is again preferred. Labetalol is an alternative although, especially in high dose, the longer half-life can be con-
sidered as a disadvantage. Experiences with landiolol are limited.  
Key Words: Electroconvulsive therapy, beta-adrenergic blocking agents, anesthesia, esmolol, labetalol, landiolol, nicardipine, 
urapidil, depressive disorder. 
INTRODUCTION 
 Electroconvulsive therapy (ECT) is a widely used and 
effective treatment for severe depression, especially when 
alternative methods of treatment have failed [1]. It is gener-
ally considered to be a low-risk procedure. However, ECT is 
accompanied by a cardiovascular response that can be dan-
gerous in patients with cardiovascular disease. This response 
consists of an initial parasympathetic and a subsequent sym-
pathetic reaction. During the electrical stimulus there is an 
immediate, brief and intense parasympathetic activity, which 
may cause a transient sinus bradycardia or, rarely, asystole. 
In some treatment centers, atropine or glycopyrrolate are 
given before induction of anesthesia to attenuate this vagal 
effect [2]. This transient vagal discharge is followed by a 
sympathetic discharge, amplified by adrenal release, which is 
responsible for the tachycardia and the hypertension ob-
served after the stimulation [3]. 
 Pretreatment screening and adequate management of 
cardiovascular risk factors remain the most important meth-
ods of preventing cardiovascular complications caused by 
ECT. In addition, attenuation of the cardiovascular response 
during ECT can be important in patients with cardiovascular 
disease or patients with prolonging hypertension and tachy-
cardia during an ECT session. 
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 Many antihypertensive drugs have been administered in 
an attempt to attenuate the acute autonomic response to ECT. 
Previously diazoxide, hydralazine, propanolol, nitroglycerine 
ointment and clonidine have been used; however, the dura-
tion of action of these agents is longer than the ECT proce-
dure and anesthesia time. Sodium nitroprusside has a short 
half-life, but reflex tachycardia and persistent hypotension 
after ECT makes this drug less useful [4].  
 Recently mostly beta-adrenergic blocking agents with 
short half-lives, especially esmolol, were studied. However, 
problems such as decrease in seizure duration, prolonged 
cardiovascular depression, and excessive hypotension have 
been reported [5-7] . In addition the use of drugs with beta-
blockade activity is limited because it is contraindicated in 
patients with significant ventricular dysfunction, conduction 
abnormalities, or bronchospastic disease. 
 In this review we want to summarize the results of the 
randomized clinical trials with beta-blocking adrenergic 
agents during ECT compared to placebo, and review the ef-
fect on seizure duration and cardiovascular variables.  
 Seizure duration is one of the variables used to assess the 
adequacy of convulsions, and reduction in seizure duration 
may interfere with therapeutic efficacy. However, the rela-
tion between therapeutic efficacy and seizure characteristics 
has recently proved to be more complicated than originally 
thought. In recent years it has become evident that seizure 
duration has little bearing on efficacy [8]. However, when 
seizure duration is less than 15 seconds in both motor and 
EEG manifestations, the likelihood is high that the seizure 
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was limited by insufficient electrical stimulation and that the 
treatment was inadequate [9]. In unilateral ECT, electrical 
doses far higher than seizure threshold also determine effi-
cacy [10]. With bilateral ECT seizure duration is related to 
efficacy as explained previously.  
 Conflicting results of the influence of beta-adrenergic 
blocking agents on seizure duration have been published. In 
this review we examine the placebo-controlled trials in 
which the effect of beta-adrenergic blocking agents on sei-
zure duration and cardiovascular parameters during ECT is 
one of the outcome criteria. Method 
 We searched for studies in the electronic databases Med-
line, and included all published articles irrespective of the 
language. Keywords combined in the search were: “beta-
adrenergic blocking agents” and “electroconvulsive ther-
apy”. The only limitation in the search was that the publica-
tion type had to be randomized controlled trials. Data on 
seizure duration or cardiovascular parameters had to be pre-
sented, all trials had to be placebo-controlled and of compa-
rable design. All publications were reviewed by two authors 
(WvdB, THNG). When results differed, consensus was 
reached between both authors. If different dosages of beta-
adrenergic blocking agents in comparison with placebo were 
used in a trial, each dosage was considered as a separate trial. 
Results 
 Our search strategy resulted in 20 publications. Two pub-
lications were not about beta-adrenergic blocking agents and 
the effect on seizure duration but explored the response of 
the psychiatric disorder to the addition of beta-adrenergic 
blocking to ECT or the usual treatment of schizophrenia [11, 
12]. Another publication reported on the effects (of among) 
others beta-blocking agents on neuroendocrine hormones 
and could not be used for the current review [13]. Several 
other publications did not mention the absolute duration of 
the seizure or did not include this outcome criterion [14-17]. 
In one study interaction between nicardipine and labetalol 
was studied, but no absolute seizure duration was reported 
between sessions with or without labetalol addition [6]. One 
study reported on the effect of esmolol on the bisprectal in-
dex scale (BIS) [18]. In that study the effect of a single es-
molol dose on the BIS was assessed. A bolus of esmolol 80 
mg was given to 30 healthy male patients after induction of 
anesthesia using propofol, with either fentanyl or placebo. 
Anesthesia was maintained using propofol to keep the BIS 
value between 55 and 60. The result suggests that a single 
dose of esmolol affects the systolic blood pressure (SBP) and 
heart rate (HR) but does not affect the BIS value. How es-
molol affects the seizure duration and EEG changes remains 
unclear. In a recent trial with nicardipine, the use of labetalol 
was an outcome criterion [19]. 
 Of the remaining publications eight were a comparison 
between esmolol and placebo, two on labetalol [15, 17] and 
one on landiolol compared to placebo [20]. 
ESMOLOL 
 Five publications used esmolol as infusion sometimes 
combined with a starting bolus [21-25]; three trials adminis-
tered solely a bolus [5, 7, 26]. For the trials with infusion 
treatment with or without a starting bolus the total dosage 
used was calculated with the mean weight of patients and the 
duration of the infusion; these calculations are given in Table 
1. One publication did not mention the average weight of the 
patients; weight was calculated by calculating the mean 
weights of all other trials and using the mean for this trial 
[24]. Another publication did not mention the mean weight 
but this could be derived from data on the dosages used for 
anesthetic and muscle relaxation [25]. For the trials with 
bolus treatment the bolus dosage to mean weight is calcu-
lated as way of comparison between these trials; these data 
are also shown in Table 1. 
 Tables 2 present data on number of patients, number of 
sessions per patient, dosages and seizure duration and sig-
nificant effects of esmolol in comparison with placebo, on 
the cardiovascular variables for each trial.  
 Esmolol significantly reduces seizure duration as meas-
ured with the cuff method in all infusion trials except one 
[23]. The cuff method consists of inflating a blood pressure 
cuff above the right knee to 300 mm Hg, before the admini-
stration of succinylcholine; because there is no neuromuscu-
lar block in the right lower leg, duration of the convulsion 
can be timed clinically. In all infusion trials cardiovascular 
variables were significantly attenuated by esmolol, diastolic 
blood pressure was attenuated only with a high dose of es-
molol [22]. In trials using bolus administration the effect on 
seizure duration are inconclusive, cardiovascular variables 
are significantly attenuated in all trials. 
LABETALOL 
 Labetalol is studied in five trials [6, 15, 17, 19, 27]. The 
first study included 11 patients (average age 70.3 years) 
identified as American Society for Anesthesiologists (ASA) 
physical class status II, III and IV, all with a concurrent 
medical disease with a refractory affective disorder [15]. As 
compared with placebo, labetalol blunted the increase in 
mean arterial pressure (MAP) and HR. Moreover, the fre-
quency of atrial arrythmias and premature ventricular con-
tractions were also significantly reduced with labetalol. Sei-
zure duration was not measured in this trial [15]. 
 In the next study, nicardipine, a dihydropyridine calcium 
antagonist was studied for hemodynamic changes during 
ECT [6]. Nicardipine was administered in three different 
dosages; with each dosage 10 mg of labetalol was adminis-
tered. Nicardipine 2.5 mg bolus i.v. in combination with la-
betalol 10 mg i.v. administered 4 minutes for induction of 
anesthesia was the most effective combination in attenuating 
the acute hypertensive response during ECT. Seizure dura-
tion was not adversely affected. The hypotensive effect of 
nicardipine was accompanied by tachycardia, implying that 
nicardapine must be administered in combination with a 
beta-adrenergic blocking agent to minimize the nicardipine 
induced increase in HR [6]. 
 In a more recent study, nicardipine was administered 
immediately before application of the ECT stimulus after 
induction of anesthesia for ECT [19]. Bolus injections of 20, 
40 and 80 μg/kg nicardipine i.v. were compared with pla-
cebo in a randomized double blind cross over study during 
four ECT sessions in 25 patients. One of the outcome criteria 
was the need of labetalol during the sessions. Nicardipine 40 
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μg/kg i.v. appeared the optimal dose because it was more 
effective in controlling the acute hypertensive response than 
the smaller dose (20 μg/kg) dose and was associated with 
less increase in HR during the ECT treatment and less de-
crease in MAP on awakening compared with the 80 μg/kg 
dose. Nicardipine did not adversely affect the duration of the 
ECT-induced seizure, regardless of the dose administered. 
Rescue treatment with labetalol was needed in the group 
with 40 μg/kg and 80 μg/kg, but significantly less than in the 
control group [19]. 
 Labetalol was also compared with urapidil, a postsynap-
tic -1-adrenergic antagonist and central serotoninergic ago-
nist, in a double-blind placebo-controlled cross over design 
in which each patient served as their own control [27]. Labe-
talol (0.2 mg/kg i.v.) and urapidil (25 mg i.v.) was adminis-
tered prior to succinylcholine. Heart rate decreased 1 minute 
after ECT and remained lower than HR values recorded at 
baseline situation with labetalol. In the control and urapidil 
group HR significantly increased compared to baseline. Both 
treatment conditions significantly attenuated the hyperten-
sive response in comparison with the control group; neither 
of the treatments had any influence on seizure duration. 
Since urapidil was able to reduce the increase in hyperten-
sive response to the ECT stimulus, this drug seems to be a 
good alternative in patients with contraindication for beta-
antagonists [27]. Urapidil has no attenuating effect on heart 
rate. 
 In an open study with a randomized block design, 18 
patients underwent ECT in each of five experimental states: 
no drug, esmolol low dose (1.3 mg/kg), esmolol high dose 
(4.4. mg/kg), labetalol low dose (0.13 mg/kg) or labetalol 
high dose (0.44 mg/kg) [17]. The drug was administered i.v. 
immediately prior to methohexital and sucinylcholine. Low 
and high doses of antihypertensive drugs significantly at-
tenuated SBP (1 and 3 minutes after ECT stimulus), diastolic 
blood pressure (DBP) (1 minute), and HR (1 and 3 minutes). 
The antihypertensive drugs in low dose produced a reduction 
of peak increases in SBP by approximately 50%, whereas 
after high doses, such increases were nearly eliminated. 
However, the high dose of labetalol had significant effects 
on SBP after 5 and 10 minutes. This can be attributed to the 
longer half-life of labetalol. Therefore esmolol may be pre-
ferred if a larger dose of beta-adrenergic blocker is contem-
plated. Seizure duration was not an outcome criterion in this 
trial [17]. 
LANDIOLOL 
 Landiolol is an ultra-short-acting beta-adrenoreceptor 
blocker (half-life 3-4 min) created by altering the chemical 
structure of esmolol to produce a greater degree of cardio-
selectivity and more potency. Landiolol (0.1 mg/kg) was 
studied in 10 patients receiving maintenance ECT once or 
twice a month at an outpatient psychiatric clinic in a random-
ized, placebo-controlled, double-blind cross-over study [20]. 
Table 1. Calculation of the Total Dose of Esmolol Administered During Treatment Sessions for Trials Using Infusion and of the 
Bolus Dosage by Mean Weight 
Publication Schedule Duration (min) Average weight (kg) Total dosage (mg) Bolus/Average weight 
(mg/kg) 
Kovac (1990) [21] 80 mg bolus, 24 
mg/min infusion 
8 64 272 1.25  
Howie (1990) [22] 500 g/kg/min 
300 g/kg/min 
4 
3 
75 292.5  
Howie (1992) [23] 500 g/kg/min bolus 
300 g/kg/min 
8 64 32 +153.6=185.6  
Howie (1992) [23] 500 g/kg/min bolus 
200 g/kg/min 
8 64 32+102.4= 134.4  
Howie (1992) [23] 500 g/kg/min bolus 
100 g/kg/min 
8 64 32+51.2=83.2  
Zvara (1997) [24] 500 g/kg 
(1 minute) 
200 g/kg/min 
12 66 33+158.4=191.4  
McCall (1997) [25] 500 g/kg 
(1 minute) 
200 g/kg/min 
11 64.2 32.1+141,2=173.3  
Kovac (1991) [5] Bolus 100 mg  70  1.4 
Kovac (1991) [5] Bolus 200 mg  70  2.8 
Weinger (1991) [13] Bolus 75.6 mg  75.6  1 
Van den Broek (1999) 
[7] 
Bolus 80 mg  63.7  1.25 
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All patients were using different antidepressive agents dur-
ing the trial. There was no significant difference in mean 
motor seizure duration between the placebo and landiolol 
sessions. Administration of landiolol prevented the increase 
in SBP at 1-3 minutes after electrical stimulus significantly 
compared to placebo. Heart rate tended to decrease (but not  
 
significantly) after landiolol administration, and was main-
tained lower than the value in the placebo session until 3 
minutes after ECT. This study only evaluated one dose of 
landiolol and only SBP and HR. Since coronary perfusion 
occurs during diastole, MAP is considered a better indication 
of coronary perfusion than SBP. This dosage did not lead to  
 
Table 2. Demographic Variables, Esmolol Dosage and Outcome Measures for Trials Using Infusion Administration and Bolus 
Administration of Esmolol 
 Esmolol Placebo 
Study n Design Total dosage 
(Table 1) 
Significant effect on 
cardiovascular variables 
Cuff (sec) EEG (sec) Cuff (sec) EEG (sec) 
Kovac (1990) 
[21] 
17 1 esmolol 1 pla-
cebo session 
272 HR 
MAP 
RPP 
 39±3  45±3 ns 
Howie (1990) 
[22] 
20 4 esmolol 
4 placebo 
292.5 HR 
SBP 
DBP 
39±14 67±28 48±18 Sign. 86±41 
Sign. 
Howie (1992) 
[23] 
20 2 esmolol 
2 placebo 
185.6 HR 
SBP 
DBP 
MAP 
36±14 56±27 42±11 Sign. 67±29 
ns 
Howie (1992) 
[23] 
20 2 esmolol 
2 placebo 
134.4 HR 
SBP 
MAP 
34±14 64±36 42±11 
Sign. 
67±29 
ns 
Howie (1992) 
[23] 
20 2 esmolol 
2 placebo 
83.2 HR 
SBP 
MAP 
38±11 62±26 42±11 
ns 
67±29 
ns 
Zvara (1997) 
[24] 
19 1.94 esmolol 
1.78 
placebo 
191.4 HR 
SBP 
MAP 
26.4±2.1 50.6±3.0 35.5±7.2  
Sign 
55.1±4.3 
ns 
McCall 
(1997) 
[25] 
18 1.55 esmolol 
1.55 placebo 
173.3  26.3±8.3 49.7±17.6 33.2±7.2 
Sign. 
53.3±17.7 
ns 
Study n Design Bolus dos-
age/mean weight 
(mg/kg) 
Significant effect on 
cardiovascular variables 
Cuff (sec) EEG (sec) Cuff (sec) EEG (sec) 
Kovac (1991) 
[5] 
12 1 esmolol 
1 placebo 
1.4 HR 
RPP 
MAP 
 44.58±4.61  52.75±4.61 
ns 
Kovac (1991) 
[5] 
12 1 esmolol 
1 placebo 
2.8 HR 
RPP 
MAP 
 40.00±3.09  52.75±4.61 
Sign. 
Weinger 
(1991) 
[13] 
10 1 esmolol 
1 placebo 
1 HR 
RPP 
SBP 
 45.8±5.9  56.5±12.5 
ns 
v.d. Broek 
(1999) 
[7] 
22 3 esmolol 
3 placebo 
1.25 HR 
MAP 
SBP 
38.7 55.1 45.6 
Sign. 
69.1 
Sign. 
HR= heart rate, MAP= mean arterial pressure, RPP= rate pressure product, SBP= systolic blood pressure, DBP= diastolic blood pressure. ns=difference between esmolol and placebo 
not significant. Sign= significant difference between placebo and esmolol. 
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hypotension or bradycardia. Perhaps a larger dose would 
also attenuate HR to a significant level. 
DISCUSSION 
 As can be derived from Table 2 in almost all trials except 
one [23] esmolol significantly shortens seizure duration as 
measured with the cuff method. With the highest dose with 
the infusion technique the seizure duration as measured with 
the EEG was also significantly shorter with esmolol [22]. In 
all infusion trials cardiovascular variables were significantly 
attenuated by esmolol. Especially HR, MAP and SBP were 
attenuated. Diastolic blood pressure was attenuated only in 
one trial with a high dosage of esmolol [22]. 
 In trials using bolus administration the effects on seizure 
duration are inconclusive. With a relatively high bolus dos-
age [5] or relatively more sessions [7] a significant attenuat-
ing effect on seizure duration is accomplished by esmolol in 
comparison with placebo.  
 A formal quantative meta-analysis of the effect of es-
molol on seizure duration in comparison with placebo could 
not be performed because in almost all trials the mean differ-
ence of seizure duration between esmolol and placebo ses-
sions and its standard error could not be derived. The rele-
vant publications lacked sufficient details on this main study 
outcome. Exact p-values for differences between conditions 
are usually not reported. In future studies when beta-blockers 
are compared with placebo it is important to at least report 
the mean difference between conditions, with either standard 
errors or accurate p-values or 95% confidence intervals, in 
order to enable a subsequent quantative meta-analysis. 
 Since the effect on seizure duration of esmolol cannot be 
determined in a systematic manner, and since the relation 
between seizure duration and efficacy of ECT is dependent 
on electrode placement, it seems advisable to use bilateral 
electrode placement with patients with cardiovascular risk 
factors and use of esmolol. One should take into account the 
possible negative effect of esmolol on seizure duration in 
these cases and adhere to the guidelines for ECT that advise 
at least 10 treatment sessions with bilateral ECT before one 
can conclude that ECT is not efficacious. Routine admini-
stration of esmolol during ECT sessions as a prophylactic 
measure is not advised [7]. 
 In the absence of cardiovascular risk factors but prolong-
ing hypertension or tachycardia during ECT sessions, es-
molol also is preferred. Labetalol is an alternative although 
(especially in high dose) the longer half-life of labetalol can 
be considered as a disadvantage. Labetalol is mostly studied 
as a rescue treatment with nicardipine and in comparison 
with urapidil. Data comparing labetalol with placebo and 
effects on seizure duration are scarce. 
 Experiences with landiolol are limited but the short half-
life, greater degree of cardio selectivity and more potency 
makes it a promising alternative. 
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